Cvetkovic Z, Cvetkovic B, Petrovic M, Ranic M, Debeljak-Martarcic J, Vucic V, Glibetic M
Department of Hematology, Clinical Hospital Center Zemun, Belgrade, Serbia.
J BUON. 2009 Jul-Sep;14(3):501-6.
The relationship between plasma lipid levels and neoplastic diseases is still unclear. The aim of this study was to analyse the lipid profile of individuals with non-Hodgkin's lymphoma (NHL) or prostate carcinoma (CaP) and to follow serum lipid levels changes in NHL patients according to their response to chemotherapy.
Forty-seven patients with NHL, 57 patients with CaP, two control groups composed of 29 and 43 age- and sex-matched healthy adults, related to NHL and CaP patients, respectively, were included in the study. Follow-up studies of NHL patients were carried out after the 3rd and 6th cycle of chemotherapy.
Initial plasma cholesterol (Chol), HDL-cholesterol (HDL-Chol) and phospholipids (PL) values were significantly lower in patients with NHL or CaP than in controls. Following chemotherapy, we noticed a progressive increase in lipid levels in NHL patients with complete remission (CR) and stable disease (SD), and further decrease in patients with the disease progression.
Decreased plasma Chol, HDL-Chol and PL levels of patients with NHL or CaP can be considered as non-specific prognostic parameters in patients with these malignancies.
血浆脂质水平与肿瘤性疾病之间的关系仍不明确。本研究的目的是分析非霍奇金淋巴瘤（NHL）或前列腺癌（CaP）患者的血脂谱，并根据NHL患者对化疗的反应跟踪其血清脂质水平变化。
本研究纳入了47例NHL患者、57例CaP患者，以及分别由29名和43名年龄及性别匹配的健康成年人组成的两个对照组，这两个对照组分别与NHL和CaP患者相关。在化疗第3周期和第6周期后对NHL患者进行随访研究。
NHL或CaP患者的初始血浆胆固醇（Chol）、高密度脂蛋白胆固醇（HDL-Chol）和磷脂（PL）值显著低于对照组。化疗后，我们注意到完全缓解（CR）和疾病稳定（SD）的NHL患者脂质水平逐渐升高，而疾病进展的患者脂质水平进一步降低。
NHL或CaP患者血浆Chol、HDL-Chol和PL水平降低可被视为这些恶性肿瘤患者的非特异性预后参数。
